Annual Compliance Report for the financial year 2024-25
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova Ltd has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under Regulation 24A of SEBI LODR Regulations. The report was certified by Sanjay Grover & Associates (Practicing Company Secretaries) after reviewing the company's filings, website, records, and SEBI compliance for the year. The Practicing Company Secretary confirmed full compliance with all applicable SEBI Regulations, including Listing Obligations, Insider Trading, Takeover Code, and Share-Based Employee Benefits norms. All 13 specific compliance areas checked — Secretarial Standards, board policies, website disclosures, director disqualification, subsidiary disclosures, document preservation, performance evaluation, related party transactions, event disclosures, insider trading, SEBI actions, auditor resignations, and other non-compliances — were marked compliant with no observations or deviations. No fines, penalties, or actions were taken by SEBI or stock exchanges against the company or its promoters/directors/subsidiaries during the review period.
This is a routine annual regulatory compliance filing with no adverse findings, no penalties, and no regulatory actions — a clean compliance report that has no material impact on the stock price but reassures shareholders about the company's governance standards.